GlassScriptPhysician profile
Celeste J Fine
NPI 1023379393
$82,323.25
in general payments reported to CMS, 2019-2025
75 companies · $20.05 in 2025
The $20.05 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $39K · 2022: $26K · 2023: $11K · 2024: $6,304 · 2025: $20.05.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,288 · Consulting Fee: $150 · Travel and Lodging: $32.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,109.48 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,287.50 |
| Consulting Fee | $150.00 |
| Travel and Lodging | $32.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $50,573.03 | 2021-2024 | |
| Biogen, INC. | $13,854.03 | 2021-2024 | Tysabri, Vumerity |
| Allergan, INC. | $1,908.05 | 2021-2022 | |
| Ucb, INC. | $1,106.28 | 2021-2024 | Briviact, Nayzilam, Rystiggo |
| Genzyme Corporation | $869.08 | 2021-2024 | |
| Lilly USA, LLC | $848.90 | 2021-2024 | Emgality, Amyvid, Reyvow |
| Upsher-Smith Laboratories LLC | $742.60 | 2021-2023 | |
| Pfizer INC. | $588.73 | 2023-2024 | |
| Teva Pharmaceuticals USA, INC. | $579.73 | 2021-2024 | Austedo Xr, Austedo |
| Neurocrine Biosciences, INC. | $563.14 | 2021-2024 | Ingrezza, Ongentys |
| Emd Serono, INC. | $528.68 | 2021-2024 | Mavenclad |
| Amgen INC. | $513.68 | 2022-2024 | Aimovig, Uplizna |
| Csl Behring | $508.71 | 2021-2024 | Hizentra, Privigen |
| Novartis Pharmaceuticals Corporation | $493.09 | 2021-2024 | |
| Banner Life Sciences, LLC | $456.07 | 2021-2024 |
Show all 75 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $435.86 | 2021-2024 | Rytary, Lyvispah |
| Argenx US, INC. | $418.64 | 2022-2024 | Vyvgart Hytrulo, Vyvgart |
| Biohaven Pharmaceutical Holding Company LTD. | $405.56 | 2022 | |
| Celgene Corporation | $379.11 | 2021-2024 | Zeposia |
| Eisai INC. | $366.05 | 2021-2024 | |
| Genentech USA, INC. | $349.43 | 2021-2024 | Ocrevus, Enspryng |
| Horizon Therapeutics Plc | $346.87 | 2021-2023 | Uplizna |
| Impel Pharmaceuticals INC. | $336.96 | 2022-2023 | Trudhesa |
| Sk Life Science, INC. | $322.97 | 2021-2024 | |
| Alexion Pharmaceuticals, INC. | $302.89 | 2021-2024 | Ultomiris |
| Otsuka America Pharmaceutical, INC. | $296.31 | 2023-2024 | Rexulti, Nuedexta |
| Lundbeck LLC | $287.89 | 2021-2024 | Vyepti, Rexulti |
| Acadia Pharmaceuticals INC | $277.13 | 2021-2024 | Nuplazid |
| Medtronic, INC. | $274.00 | 2021-2024 | Percept PC Brainsense, Sensight, Intellis Adaptivestim |
| Biohaven Pharmaceuticals, INC. | $260.77 | 2021 | |
| Merz Pharmaceuticals, LLC | $250.56 | 2021-2024 | Xeomin |
| Avion Pharmaceuticals | $240.10 | 2022-2023 | Dhivy |
| Acorda Therapeutics, INC | $233.20 | 2021-2024 | Ampyra, Inbrija |
| Tg Therapeutics, INC. | $209.96 | 2023-2024 | |
| Mdd US Operations, LLC | $160.18 | 2021-2024 | Apokyn, Apokyn |
| Kyowa Kirin, INC. | $123.47 | 2021-2024 | Nourianz |
| Almatica Pharma LLC | $123.10 | 2021-2023 | Gralise |
| Catalyst Pharmaceuticals, INC. | $120.73 | 2022-2024 | Fycompa, Firdapse |
| Sumitomo Pharma America, INC. | $101.01 | 2023-2024 | Aptiom |
| Alnylam Pharmaceuticals INC. | $99.19 | 2021-2024 | Onpattro, Amvuttra |
| Grifols USA, LLC | $92.93 | 2022-2024 | Gamunex-C |
| Abbott Laboratories | $89.14 | 2021-2025 | Infinity, Proclaim |
| Corium, LLC | $88.25 | 2022-2023 | Adlarity |
| Janssen Pharmaceuticals, INC | $83.92 | 2021-2022 | |
| Octapharma USA, INC. | $66.57 | 2024 | Octagam Immune Globulin (Human), Panzyga |
| Astrazeneca Pharmaceuticals LP | $63.47 | 2021-2023 | Evusheld, Flumist Quadrivalent |
| Ipsen Biopharmaceuticals, INC | $62.06 | 2023 | Dysport |
| Neurelis, INC. | $58.97 | 2022-2024 | Valtoco |
| Ani Pharmaceuticals, INC. | $55.04 | 2023-2024 | Purified Cortrophin Gel |
| Sunovion Pharmaceuticals INC. | $53.27 | 2021 | |
| Collegium Pharmaceutical, INC. | $47.01 | 2022 | |
| Aprecia Pharmaceuticals, LLC | $44.62 | 2022-2023 | Spritam |
| Nevro Corp. | $42.18 | 2021 | |
| Jazz Pharmaceuticals INC. | $41.85 | 2022-2023 | |
| Avanir Pharmaceuticals, INC. | $38.99 | 2021-2022 | |
| Nalu Medical, INC. | $38.76 | 2024 | Nalu Neurostimulation System |
| Mallinckrodt Hospital Products INC. | $38.48 | 2024 | Acthar |
| Boston Scientific Corporation | $35.78 | 2021-2023 | Watchman Flx |
| Supernus Pharmaceuticals, INC. | $34.86 | 2022 | |
| Saluda Medical Americas, INC. | $33.52 | 2024 | Evoke |
| Adamas Pharmaceuticals, INC. | $31.91 | 2021 | |
| Otto Bock Healthcare LP | $31.49 | 2023 | |
| Sandoz INC. | $30.57 | 2024 | |
| Currax Pharmaceuticals LLC | $30.42 | 2021 | |
| Tersera Therapeutics LLC | $27.25 | 2024 | Quzyttir |
| Cala Health, INC. | $26.19 | 2022 | |
| Merz North America, INC. | $24.94 | 2022 | |
| Merck Sharp & Dohme LLC | $24.82 | 2021 | |
| Averitas Pharma INC. | $23.78 | 2023 | Qutenza |
| Harmony Biosciences LLC | $21.26 | 2024 | |
| Grt US Holding, INC. | $20.67 | 2021-2022 | |
| Arbor Pharmaceuticals, INC. | $20.65 | 2021 | |
| Scilex Pharmaceuticals INC. | $16.87 | 2024 | |
| Tanabe Pharma America, INC. | $16.47 | 2022 | |
| Metacel Pharmaceuticals LLC | $10.55 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Celeste Fine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.